Check-Cap Ltd (NASDAQ: CHEK) (NASDAQ: CHEKW), (NASDAQ: CHEKZ), a clinical stage medical diagnostics company advancing the development of C-Scan, an ingestible capsule for the prevention of colorectal cancer, announced yesterday its financial results for the first quarter ended 31 March 2019.
The company reported research and development expenses at USD2.3m for the three months ended 31 March 2019, compared to USD1.6m for the same period in 2018.
The firm posted an operating loss of USD3.2m for the three months ended 31 March 2019, as against an operating loss of USD2.1m for the same period in 2018.
Spinogenix reveals positive SPG302 topline results from Phase 2a study for treatment of ALS
iLeukon reports FDA clearance of IND application for phase II study of ILKN421H in advanced NSCLC
AVEO Oncology signs development and option agreement with HiberCell
Merck assumes full development rights for investigational antibody MK-8690
UCB's KYGEVVI receives FDA approval for TK2d treatment
Camurus launches Oczyesa in Germany for patients with acromegaly
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Kiora Pharmaceuticals joins Global Genes' RARE-X Vision Consortium
Pilatus Biosciences to present new preclinical data on PLT012 at SITC 2025
Rovia Clinical Research opens new clinical research site in Hattiesburg, Mississippi